Evidence for Gender-Specific Transcriptional Profiles of Nigral Dopamine Neurons in Parkinson Disease
暂无分享,去创建一个
Ming Yi | Robert Stephens | R. Stephens | Yulei N. Wang | M. Yi | K. Sonntag | Yulei Wang | Filip Simunovic | Kai C. Sonntag | F. Šimunović
[1] E. Perry,et al. Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies , 2007, Movement disorders : official journal of the Movement Disorder Society.
[2] L. Martin,et al. Motor neuron degeneration in amyotrophic lateral sclerosis mutant superoxide dismutase‐1 transgenic mice: Mechanisms of mitochondriopathy and cell death , 2007, The Journal of comparative neurology.
[3] B. Kaspar,et al. Gene-targeted therapies for the central nervous system. , 2008, Archives of neurology.
[4] E. Hirsch,et al. Role of activity‐dependent mechanisms in the control of dopaminergic neuron survival , 2007, Journal of neurochemistry.
[5] N. Wood,et al. Molecular basis of Parkinson's disease. , 2009, Neuroreport.
[6] Xiao-hong Cai,et al. Potassium channels: possible new therapeutic targets in Parkinson's disease. , 2008, Medical hypotheses.
[7] Nobutaka Hattori,et al. Prognosis of Parkinson's disease: Time to stage III, IV, V, and to motor fluctuations , 2006, Movement disorders : official journal of the Movement Disorder Society.
[8] PINK1 Protects against Oxidative Stress by Phosphorylating Mitochondrial Chaperone TRAP1 , 2007, PLoS biology.
[9] R. Stephens,et al. SLEPR: A Sample-Level Enrichment-Based Pathway Ranking Method — Seeking Biological Themes through Pathway-Level Consistency , 2008, PloS one.
[10] K. Lim,et al. Protein misfolding and aggregation in Parkinson's disease. , 2009, Antioxidants & redox signaling.
[11] J. Downing,et al. Murine Leukemias with Retroviral Insertions at Lmo2 Are Predictive of the Leukemias Induced in SCID-X1 Patients Following Retroviral Gene Therapy , 2009, PLoS genetics.
[12] Wei Jiang,et al. Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. , 2009, The Journal of clinical investigation.
[13] J. Connor,et al. Analysis of ferritin genes in Parkinson disease. , 2007, Clinical chemistry and laboratory medicine.
[14] D. Berg,et al. Disturbance of iron metabolism in Parkinson’s disease — ultrasonography as a biomarker , 2009, Neurotoxicity Research.
[15] R. Stephens,et al. Chromatin-Associated Genes Protect the Yeast Genome From Ty1 Insertional Mutagenesis , 2008, Genetics.
[16] Christine A. Wells,et al. A Cross-Study Transcriptional Analysis of Parkinson's Disease , 2009, PloS one.
[17] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[18] Lorene M Nelson,et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. , 2003, American journal of epidemiology.
[19] D. Burn. Sex and Parkinson’s disease: a world of difference? , 2007, Journal of Neurology Neurosurgery & Psychiatry.
[20] Martyn N J Paley,et al. MRI assessment of basal ganglia iron deposition in Parkinson's disease , 2008, Journal of magnetic resonance imaging : JMRI.
[21] D. Twelves,et al. Systematic review of incidence studies of Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.
[22] Michel Goedert,et al. Tau protein and neurodegeneration. , 2004, Seminars in cell & developmental biology.
[23] R. Stephens,et al. Differences in the Tumor Microenvironment between African-American and European-American Breast Cancer Patients , 2009, PloS one.
[24] Sonja W. Scholz,et al. Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data , 2006, The Lancet Neurology.
[25] Y. Gupta,et al. Status of antioxidant defense system and expression of toxicant responsive genes in striatum of maneb- and paraquat-induced Parkinson's disease phenotype in mouse: Mechanism of neurodegeneration , 2006, Brain Research.
[26] J. Growdon,et al. Molecular markers of early Parkinson's disease based on gene expression in blood , 2007, Proceedings of the National Academy of Sciences.
[27] H. Braak,et al. Invited Article: Nervous system pathology in sporadic Parkinson disease , 2008, Neurology.
[28] Houeto Jean-Luc. [Parkinson's disease]. , 2022, La Revue du praticien.
[29] S. Leurgans,et al. Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. , 2004, Archives of neurology.
[30] G. Wooten,et al. Are men at greater risk for Parkinson’s disease than women? , 2004, Journal of Neurology, Neurosurgery & Psychiatry.
[31] R. Stephens,et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. , 2008, Cancer research.
[32] Robyn L Prueitt,et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. , 2008, Cancer research.
[33] Wolfgang Wurst,et al. Fate of Midbrain Dopaminergic Neurons Controlled by the Engrailed Genes , 2001, The Journal of Neuroscience.
[34] R. E. Burke. Programmed cell death and new discoveries in the genetics of parkinsonism , 2008, Journal of neurochemistry.
[35] M. Quik,et al. Nicotinic receptors as CNS targets for Parkinson's disease. , 2007, Biochemical pharmacology.
[36] C. Wilhelm,et al. Different Microtubule Motors Move Early and Late Endocytic Compartments , 2008, Traffic.
[37] X. Su,et al. Genome-Wide Compensatory Changes Accompany Drug- Selected Mutations in the Plasmodium falciparum crt Gene , 2008, PloS one.
[38] M. Mattson,et al. Mitochondria in Neuroplasticity and Neurological Disorders , 2008, Neuron.
[39] John N Weinstein,et al. A stromal gene signature associated with inflammatory breast cancer , 2008, International journal of cancer.
[40] M. Elstner,et al. Individual dopaminergic neurons show raised iron levels in Parkinson disease , 2007, Neurology.
[41] D. Surmeier,et al. Calcium, ageing, and neuronal vulnerability in Parkinson's disease , 2007, The Lancet Neurology.
[42] J. A. Cook,et al. Heterogeneity in male to female risk for Parkinson’s disease , 2007, Journal of Neurology, Neurosurgery & Psychiatry.
[43] D. Stephan,et al. A survey of genetic human cortical gene expression , 2007, Nature Genetics.
[44] L. Moran,et al. Analysis of alpha-synuclein, dopamine and parkin pathways in neuropathologically confirmed parkinsonian nigra , 2007, Acta Neuropathologica.
[45] C. Ríos,et al. Free Copper, Ferroxidase and SOD1 Activities, Lipid Peroxidation and NOx Content in the CSF. A Different Marker Profile in Four Neurodegenerative Diseases , 2008, Neurochemical Research.
[46] Benjamin W. H. Lim,et al. Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars , 2007, Proceedings of the National Academy of Sciences.
[47] Mostafa Ronaghi,et al. Whole genome survey of coding SNPs reveals a reproducible pathway determinant of Parkinson disease , 2008, Human mutation.
[48] G. Mellick. CYP450, genetics and Parkinson's disease: gene x environment interactions hold the key. , 2006, Journal of neural transmission. Supplementum.
[49] R. Uitti,et al. Defining the Parkinson's disease phenotype: initial symptoms and baseline characteristics in a clinical cohort. , 2005, Parkinsonism & related disorders.
[50] R. Stephens,et al. Altered Gene Expression Profiles Define Pathways in Colorectal Cancer Cell Lines Affected by Celecoxib , 2008, Cancer Epidemiology Biomarkers & Prevention.
[51] T. Gasser,et al. DJ-1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders. , 2009, Free radical biology & medicine.
[52] R. Krüger,et al. Review: Familial Parkinson's disease – genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease , 2008, Neuropathology and applied neurobiology.
[53] F Vaglini,et al. Cytochrome P450 and Parkinson's disease: protective role of neuronal CYP 2E1 from MPTP toxicity. , 2006, Journal of neural transmission. Supplementum.
[54] George A. Calin,et al. Expression of microRNAs and protein‐coding genes associated with perineural invasion in prostate cancer , 2008, The Prostate.
[55] R. Tyndale,et al. Nicotine induces brain CYP enzymes: relevance to Parkinson's disease. , 2006, Journal of neural transmission. Supplementum.
[56] Fang Yang,et al. MPP+ impairs autophagic clearance of alpha-synuclein by impairing the activity of dynein , 2009, Neuroreport.
[57] Mariza de Andrade,et al. High-resolution whole-genome association study of Parkinson disease. , 2005, American journal of human genetics.
[58] Ming Yi,et al. Seeking unique and common biological themes in multiple gene lists or datasets: pathway pattern extraction pipeline for pathway-level comparative analysis , 2009, BMC Bioinformatics.
[59] M. Frosch,et al. Effects of gender on nigral gene expression and parkinson disease , 2007, Neurobiology of Disease.
[60] M. Delong,et al. Prevalence of vitamin d insufficiency in patients with Parkinson disease and Alzheimer disease. , 2008, Archives of neurology.
[61] K. Doheny,et al. Genomewide association study for susceptibility genes contributing to familial Parkinson disease , 2009, Human Genetics.
[62] Bastiaan R Bloem,et al. Gender differences in Parkinson’s disease , 2006, Journal of Neurology, Neurosurgery & Psychiatry.
[63] Andrew B West,et al. Molecular pathophysiology of Parkinson's disease. , 2005, Annual review of neuroscience.
[64] F. Benes,et al. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. , 2009, Brain : a journal of neurology.
[65] T. Nagatsu. [Biochemistry of Parkinson's disease]. , 1988, Seikagaku. The Journal of Japanese Biochemical Society.